Htg Molecular Dia Cmn (HTGM) 2.49 $HTGM Dr. Ann
Post# of 273240
Posted On: 09/25/2016 11:13:10 AM
Htg Molecular Dia Cmn (HTGM) 2.49 $HTGM
Dr. Ann Hanham Joins HTG Molecular Diagnostics' Board of Directors
GlobeNewswire - Mon Aug 29, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham, Ph.D. has been appointed to its Board of Directors ("Board"
.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics Reports Second Quarter 2016 Results
GlobeNewswire - Tue Aug 09, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and six month periods ended June 30, 2016.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
GlobeNewswire - Thu Jul 28, 3:05PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016 in Boston.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Hold 2016 Second Quarter Financial Results Conference Call on August 9, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 second quarter financial results after market close on Tuesday, August 9, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Tuesday, August 9 to discuss these results and answer questions.
HTGM: 2.49 (+0.08)
Slone Partners Places VP of North American Capital Sales at HTG Molecular Diagnostics
PRWeb - Fri Jun 24, 2:25AM CDT
National recruitment firm Slone Partners is pleased to announce the placement of Suzanne Hill, a life sciences executive with extensive sequencing and genomics experience, as Vice President of North American Capital Sales at HTG Molecular.
HTGM: 2.49 (+0.08)
HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform
GlobeNewswire - Mon Jun 20, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for NGS-based molecular profiling applications, today announced the appointment of Suzanne Hill as Vice President of North American Capital Sales.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ("HTG" , a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3-7, 2016 in Chicago, IL.
HTGM: 2.49 (+0.08), CGIX: 1.76 (-0.06)
HTG Molecular Diagnostics Reports First Quarter 2016 Results
GlobeNewswire - Thu May 12, 3:05PM CDT
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three months ended March 31, 2016.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb
GlobeNewswire - Thu May 12, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb's translational research activities.
HTGM: 2.49 (+0.08), BMY: 56.48 (+0.06)
Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics
GlobeNewswire - Tue May 03, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Donnie (Don) M. Hardison has been appointed to its Board of Directors ("Board" .
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Hold 2016 First Quarter Financial Results Conference Call on May 12, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 first quarter financial results after market close on Thursday, May 12, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, May 12 to discuss these results and answer questions.
HTGM: 2.49 (+0.08)
Global Liquid Biopsy Markets Market Size, Strategies and Forecasts 2016 to 2020
M2 - Tue Jan 26, 4:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/v2x28v/liquid_biopsy) has announced the addition of the "Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2016 to 2020" report to their offering. The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. Use independent research that makes you the expert. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity? Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Liquid Biopsy Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Sizes Companies Mentioned - ASCO - AdnaGen (now Qiagen) - Agena Bioscience - Angle plc - ApoCell - AstraZeneca - Baylor - Bio-Rad Laboratories - BioFluidica - Biocept - Biodesix - Boreal Genomics - Broad Institute - CRUK Manchester Institute - Chronix Biomedical - Clearbridge BioMedics - Cynvenio - CytoTrack - Cytolumina Technologies Corp - Diagnologix LLC - Epic Sciences - Exosome - Fluidigm Corp - Fluxion Biosciences - GRAIL - Genomic Health - Guardant Health - HTG Molecular Diagnostics - HansaBiomed - Horizon Discovery - Illumina - Inivata - Janssen Diagnostics - Merck Serono - Molecular MD For more information visit http://www.researchandmarkets.com/research/v2...uid_biopsy
FLDM: 8.57 (-0.06), MRK: 62.96 (-0.06), HTGM: 2.49 (+0.08), GHDX: 28.84 (-0.30)
Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream
ACCESSWIRE - Fri Jan 15, 8:35AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 15, 2016 / Pressure BioSciences Inc. (OTCQB: PBIO) just announced that it exceeded its $5 million fundraising goal and approved the opening of an additional $1.25 million over-subscription amount in its PIPE offering. With growing revenue, a new multi-national partner (see below), and a potential up-listing in the near future, accredited investors have been flocking into the company's stock through the private offering, and retail investors have been flocking into the company's stock in the open market. Both of these may be bullish signs for individual investors for the coming year.
HBIO: 2.88 (+0.03), TMO: 157.66 (unch), HTGM: 2.49 (+0.08), DHR: 77.59 (-0.08), WAT: 157.67 (-0.15)
Molecular Diagnostics in Cancer Testing 2016 - New Technologies and Applications Being Continually Added
M2 - Wed Jan 13, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/2m62l5/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" report to their offering. Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned - Abbott Molecular Diagnostics - Accugenomics, Inc. - Agendia - Ambry Genetics - Biodesix - bioM?rieux - bioTheranostics (AviaraDx) - Cancer Genetics, Inc. - Clarient, Inc. (GE Healthcare) - Counsyl - Flatiron Health - Epigenomics - Exact Sciences Corporation - Exiqon - Genomic Health, Inc. - Genoptix, Inc. (Novartis) - Genmark Diagnostics - Genomictree - HTG Molecular Diagnostics - Invitae - LabCorp - Myriad Genetics, Inc. - Nanostring - Neogenomics - NSTG - Nuvera Biosciences - Orion Genomics - Pathway Genomics - Personal Genome Diagnostics - Quest Diagnostics - Rosetta Genomics Ltd. - Signal Genetics - Source MDx - Wilex, Inc. For more information visit http://www.researchandmarkets.com/research/2m62l5/molecular
SGNL: 0.52 (+0.01), MYGN: 21.67 (+0.17), DGX: 85.44 (-0.29), HTGM: 2.49 (+0.08), EXAS: 20.16 (-1.29), GHDX: 28.84 (-0.30), CGIX: 1.76 (-0.06), NVS: 81.48 (-0.55)
Global Genetic Testing Market Report 2015 - Size, Strategies and Forecasts 2016-2020
M2 - Thu Dec 10, 2:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/w9gfhq/the_global) has announced the addition of the "The Global Genetic Testing Market Size, Strategies and Forecasts 2016 to 2020" report to their offering. The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2020. The report includes detailed breakouts for 14 countries and 5 regions. Predictive Diagnostics? Pharmacogenomic Testing? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Genetic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of Genetic Testing Companies Mentioned - 35 of the 80 Companies Featured - 14M Genomics - 23andMe - Abbott Laboratories - Agena Bioscience - Agendia - Becton, Dickinson & Co. - Biofortuna - BioMerieux - BioReference Laboratories, Inc. - Bloom Burton - Cytogenetics - DiaCarta - DioGenix - Enzo Biochem - Epic Sciences - Firefly - Foundation Medicine - Genentech - Google - Great Basin Scientific - Grifols - Hologic - HTG Molecular Diagnostics - Lifecode - MDx Firm Diagnovus - MDxHealth - Merck Serono - Myriad Genetics - NanoString Technologies - Novacyt - Nuclea Bio - Precipio Diagnostics - Roche Molecular Diagnostics - Siemens Healthcare - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/w9gfhq/the_global
ABT: 42.19 (-0.03), MYGN: 21.67 (+0.17), BDX: 179.50 (-2.05), NSTG: 19.26 (-0.51), FMI: 24.16 (-0.30), ENZ: 5.13 (-0.07), MRK: 62.96 (-0.06), HTGM: 2.49 (+0.08), HOLX: 38.45 (-0.33)
HTG Molecular Diagnostics elects Jim LaFrance to board
M2 - Thu Dec 03, 5:31AM CST
Precision medicine company HTG Molecular Diagnostics (NasdaqGM:HTGM) announced on Wednesday the addition of Jim LaFrance to its board of directors.
HTGM: 2.49 (+0.08)
James (Jim) LaFrance Joins the Board of Directors of HTG Molecular Diagnostics
GlobeNewswire - Wed Dec 02, 3:01PM CST
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced today that Jim LaFrance has been appointed to its Board of Directors.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and nine months ended September 30, 2015.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Present at the Canaccord Genuity Medical Technologies and Diagnostics Forum
GlobeNewswire - Thu Nov 05, 3:02PM CST
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Medical Technologies and Diagnostics Forum on Thursday, November 19, 2015 in New York.
HTGM: 2.49 (+0.08)
Lee R. McCracken Joins the Board of Directors of HTG Molecular Diagnostics
GlobeNewswire - Tue Oct 27, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced today that Lee R. McCracken has been appointed to its Board of Directors.
HTGM: 2.49 (+0.08)
Dr. Ann Hanham Joins HTG Molecular Diagnostics' Board of Directors
GlobeNewswire - Mon Aug 29, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham, Ph.D. has been appointed to its Board of Directors ("Board"
. HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics Reports Second Quarter 2016 Results
GlobeNewswire - Tue Aug 09, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and six month periods ended June 30, 2016.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
GlobeNewswire - Thu Jul 28, 3:05PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016 in Boston.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Hold 2016 Second Quarter Financial Results Conference Call on August 9, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 second quarter financial results after market close on Tuesday, August 9, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Tuesday, August 9 to discuss these results and answer questions.
HTGM: 2.49 (+0.08)
Slone Partners Places VP of North American Capital Sales at HTG Molecular Diagnostics
PRWeb - Fri Jun 24, 2:25AM CDT
National recruitment firm Slone Partners is pleased to announce the placement of Suzanne Hill, a life sciences executive with extensive sequencing and genomics experience, as Vice President of North American Capital Sales at HTG Molecular.
HTGM: 2.49 (+0.08)
HTG Molecular Appoints New Vice President of North American Capital Sales for the HTG EdgeSeq Platform
GlobeNewswire - Mon Jun 20, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for NGS-based molecular profiling applications, today announced the appointment of Suzanne Hill as Vice President of North American Capital Sales.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
GlobeNewswire - Mon Jun 06, 7:00AM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ("HTG"
, a provider of instruments and reagents for molecular profiling applications, and Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" , a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the acceptance of a study by the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting, June 3-7, 2016 in Chicago, IL. HTGM: 2.49 (+0.08), CGIX: 1.76 (-0.06)
HTG Molecular Diagnostics Reports First Quarter 2016 Results
GlobeNewswire - Thu May 12, 3:05PM CDT
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three months ended March 31, 2016.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb
GlobeNewswire - Thu May 12, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types. The collaboration between HTG and Bristol-Myers Squibb will utilize the next generation sequencing (NGS)-based HTG EdgeSeq system as a tool for use in support of Bristol-Myers Squibb's translational research activities.
HTGM: 2.49 (+0.08), BMY: 56.48 (+0.06)
Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics
GlobeNewswire - Tue May 03, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Donnie (Don) M. Hardison has been appointed to its Board of Directors ("Board"
. HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Hold 2016 First Quarter Financial Results Conference Call on May 12, 2016
GlobeNewswire - Mon May 02, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that the Company will release 2016 first quarter financial results after market close on Thursday, May 12, 2016. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Thursday, May 12 to discuss these results and answer questions.
HTGM: 2.49 (+0.08)
Global Liquid Biopsy Markets Market Size, Strategies and Forecasts 2016 to 2020
M2 - Tue Jan 26, 4:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/v2x28v/liquid_biopsy) has announced the addition of the "Liquid Biopsy Markets Global Market Size, Strategies and Forecasts 2016 to 2020" report to their offering. The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. Use independent research that makes you the expert. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity? Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Liquid Biopsy Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Sizes Companies Mentioned - ASCO - AdnaGen (now Qiagen) - Agena Bioscience - Angle plc - ApoCell - AstraZeneca - Baylor - Bio-Rad Laboratories - BioFluidica - Biocept - Biodesix - Boreal Genomics - Broad Institute - CRUK Manchester Institute - Chronix Biomedical - Clearbridge BioMedics - Cynvenio - CytoTrack - Cytolumina Technologies Corp - Diagnologix LLC - Epic Sciences - Exosome - Fluidigm Corp - Fluxion Biosciences - GRAIL - Genomic Health - Guardant Health - HTG Molecular Diagnostics - HansaBiomed - Horizon Discovery - Illumina - Inivata - Janssen Diagnostics - Merck Serono - Molecular MD For more information visit http://www.researchandmarkets.com/research/v2...uid_biopsy
FLDM: 8.57 (-0.06), MRK: 62.96 (-0.06), HTGM: 2.49 (+0.08), GHDX: 28.84 (-0.30)
Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream
ACCESSWIRE - Fri Jan 15, 8:35AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 15, 2016 / Pressure BioSciences Inc. (OTCQB: PBIO) just announced that it exceeded its $5 million fundraising goal and approved the opening of an additional $1.25 million over-subscription amount in its PIPE offering. With growing revenue, a new multi-national partner (see below), and a potential up-listing in the near future, accredited investors have been flocking into the company's stock through the private offering, and retail investors have been flocking into the company's stock in the open market. Both of these may be bullish signs for individual investors for the coming year.
HBIO: 2.88 (+0.03), TMO: 157.66 (unch), HTGM: 2.49 (+0.08), DHR: 77.59 (-0.08), WAT: 157.67 (-0.15)
Molecular Diagnostics in Cancer Testing 2016 - New Technologies and Applications Being Continually Added
M2 - Wed Jan 13, 6:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/2m62l5/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" report to their offering. Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics 3. Cancer Diagnostics Molecular Testing Market 4. Molecular Diagnostic Tests for Cancer 5. Business 6. Reimbursement and Billing 7. Government Regulation 8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development 9. Company Profiles Companies Mentioned - Abbott Molecular Diagnostics - Accugenomics, Inc. - Agendia - Ambry Genetics - Biodesix - bioM?rieux - bioTheranostics (AviaraDx) - Cancer Genetics, Inc. - Clarient, Inc. (GE Healthcare) - Counsyl - Flatiron Health - Epigenomics - Exact Sciences Corporation - Exiqon - Genomic Health, Inc. - Genoptix, Inc. (Novartis) - Genmark Diagnostics - Genomictree - HTG Molecular Diagnostics - Invitae - LabCorp - Myriad Genetics, Inc. - Nanostring - Neogenomics - NSTG - Nuvera Biosciences - Orion Genomics - Pathway Genomics - Personal Genome Diagnostics - Quest Diagnostics - Rosetta Genomics Ltd. - Signal Genetics - Source MDx - Wilex, Inc. For more information visit http://www.researchandmarkets.com/research/2m62l5/molecular
SGNL: 0.52 (+0.01), MYGN: 21.67 (+0.17), DGX: 85.44 (-0.29), HTGM: 2.49 (+0.08), EXAS: 20.16 (-1.29), GHDX: 28.84 (-0.30), CGIX: 1.76 (-0.06), NVS: 81.48 (-0.55)
Global Genetic Testing Market Report 2015 - Size, Strategies and Forecasts 2016-2020
M2 - Thu Dec 10, 2:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/w9gfhq/the_global) has announced the addition of the "The Global Genetic Testing Market Size, Strategies and Forecasts 2016 to 2020" report to their offering. The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating new life for the industry. The report forecasts the market size out to 2020. The report includes detailed breakouts for 14 countries and 5 regions. Predictive Diagnostics? Pharmacogenomic Testing? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Genetic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of Genetic Testing Companies Mentioned - 35 of the 80 Companies Featured - 14M Genomics - 23andMe - Abbott Laboratories - Agena Bioscience - Agendia - Becton, Dickinson & Co. - Biofortuna - BioMerieux - BioReference Laboratories, Inc. - Bloom Burton - Cytogenetics - DiaCarta - DioGenix - Enzo Biochem - Epic Sciences - Firefly - Foundation Medicine - Genentech - Google - Great Basin Scientific - Grifols - Hologic - HTG Molecular Diagnostics - Lifecode - MDx Firm Diagnovus - MDxHealth - Merck Serono - Myriad Genetics - NanoString Technologies - Novacyt - Nuclea Bio - Precipio Diagnostics - Roche Molecular Diagnostics - Siemens Healthcare - Thermo Fisher For more information visit http://www.researchandmarkets.com/research/w9gfhq/the_global
ABT: 42.19 (-0.03), MYGN: 21.67 (+0.17), BDX: 179.50 (-2.05), NSTG: 19.26 (-0.51), FMI: 24.16 (-0.30), ENZ: 5.13 (-0.07), MRK: 62.96 (-0.06), HTGM: 2.49 (+0.08), HOLX: 38.45 (-0.33)
HTG Molecular Diagnostics elects Jim LaFrance to board
M2 - Thu Dec 03, 5:31AM CST
Precision medicine company HTG Molecular Diagnostics (NasdaqGM:HTGM) announced on Wednesday the addition of Jim LaFrance to its board of directors.
HTGM: 2.49 (+0.08)
James (Jim) LaFrance Joins the Board of Directors of HTG Molecular Diagnostics
GlobeNewswire - Wed Dec 02, 3:01PM CST
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced today that Jim LaFrance has been appointed to its Board of Directors.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and nine months ended September 30, 2015.
HTGM: 2.49 (+0.08)
HTG Molecular Diagnostics to Present at the Canaccord Genuity Medical Technologies and Diagnostics Forum
GlobeNewswire - Thu Nov 05, 3:02PM CST
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Canaccord Genuity Medical Technologies and Diagnostics Forum on Thursday, November 19, 2015 in New York.
HTGM: 2.49 (+0.08)
Lee R. McCracken Joins the Board of Directors of HTG Molecular Diagnostics
GlobeNewswire - Tue Oct 27, 3:01PM CDT
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, announced today that Lee R. McCracken has been appointed to its Board of Directors.
HTGM: 2.49 (+0.08)
(0)
(0)Scroll down for more posts ▼